Table 3.
Multivariable competing risks Cox proportional hazards regression evaluating risk of cirrhosis.
| HR | 95% CI | p value | |
|---|---|---|---|
| HBeAg status | |||
| HBeAg negative | Reference | ||
| HBeAg positive | 0.91 | (0.69, 1.21) | 0.5228 |
| HBsAg during follow-up | |||
| HBsAg positive | Reference | ||
| HBsAg negative | 0.59 | (0.32, 1.07) | 0.0831 |
| HBV DNA during follow-up | |||
| HBV DNA <2,000 IU/ml | Reference | ||
| HBV DNA ≥2,000 IU/ml | 1.13 | (0.71, 1.80) | 0.6066 |
| Sex | |||
| Female | Reference | ||
| Male | 8.58 | (1.19, 61.60) | 0.0326 |
| Race/ethnicity | |||
| Asian or Pacific Islander | Reference | ||
| Black or African American | 1.12 | (0.65, 1.92) | 0.6824 |
| Hispanic | 1.71 | (0.4, 3.97) | 0.2136 |
| Non-Hispanic White | 1.65 | (0.97, 2.83) | 0.0663 |
| Age | |||
| 18-39 years | Reference | ||
| 40-59 years | 1.26 | (0.64, 2.51) | 0.5016 |
| 60 years and over | 1.13 | (0.55, 2.36) | 0.7367 |
| BMI categories | |||
| 18.0–24.9 | Reference | ||
| 25.0–29.9 | 0.99 | (0.69, 1.43) | 0.9714 |
| 30.0–34.9 | 1.14 | (0.77, 1.70) | 0.5120 |
| 35.0 and over | 1.43 | (0.93, 2.20) | 0.1024 |
| Comorbidities | |||
| No diabetes | Reference | ||
| Yes diabetes | 1.32 | (0.96, 1.80) | 0.0854 |
| No hypertension | Reference | ||
| Yes hypertension | 1.21 | (0.85, 1.73) | 0.2891 |
| Alcohol use categories | |||
| No alcohol | Reference | ||
| Mild alcohol | 0.83 | (0.61, 1.12) | 0.2266 |
| Moderate to heavy alcohol | 0.79 | (0.54, 1.16) | 0.2330 |
| Tobacco use categories | |||
| Never | Reference | ||
| Past history of tobacco | 1.12 | (0.78, 1.61) | 0.5500 |
| Active current tobacco | 1.41 | (1.02, 1.93) | 0.0352 |
| FIB-4 categories | |||
| FIB-4 score <1.45 | Reference | ||
| FIB-4 score 1.45-3.25 | 2.61 | (1.77, 3.87) | <0.0001 |
| FIB-4 score >3.25 | 5.55 | (3.66, 8.41) | <0.0001 |
Multivariable competing risks Cox proportional hazards regression model was used to evaluate for predictors of cirrhosis risk. Multivariable model adjusted for HBeAg status, age, sex, race/ethnicity, BMI, diabetes, hypertension, alcohol use, tobacco use, and FIB-4 score. P < 0.05 was used to evaluate significant differences between groups. FIB-4, fibrosis-4; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma.